Tisotumab Vedotin

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 122 publications

Establishment of an Onco-Ophthalmology Collaboration for Tisotumab Vedotin and Initial Experience with Ocular Adverse Events

Establishment of an Onco-Ophthalmology Collaboration for Tisotumab Vedotin and Initial Experience with Ocular Adverse Events

Journal: Gan to kagaku ryoho. Cancer & chemotherapy

Published: August 04, 2026

Targeted Anti-TF Antibody-Drug Conjugates in Advanced Cervical Cancer-Tisotumab Vedotin-Systematic Review.

Targeted Anti-TF Antibody-Drug Conjugates in Advanced Cervical Cancer-Tisotumab Vedotin-Systematic Review.

Journal: Cancers

Published: July 08, 2026

Diverse Conjunctival Adverse Events Associated with Tisotumab Vedotin.

Diverse Conjunctival Adverse Events Associated with Tisotumab Vedotin.

Journal: Ophthalmology

Published: June 03, 2026

Multi-target-directed drugs: new additions in 2025 and post-marketing safety surveillance of drugs marketed in 2022-2024.

Multi-target-directed drugs: new additions in 2025 and post-marketing safety surveillance of drugs marketed in 2022-2024.

Journal: Pharmacological reports : PR

Published: June 02, 2026

Preclinical activity of tisotumab vedotin, an antibody-drug conjugate targeting tissue factor, in uterine serous carcinoma.

Preclinical activity of tisotumab vedotin, an antibody-drug conjugate targeting tissue factor, in uterine serous carcinoma.

Journal: Gynecologic oncology

Published: May 29, 2026

Patient-reported outcomes with tisotumab vedotin versus chemotherapy in patients with recurrent or metastatic cervical cancer: post hoc analyses from the open-label, randomized, phase 3 ENGOT-cx12/GOG-3057/innovaTV 301 trial.

Patient-reported outcomes with tisotumab vedotin versus chemotherapy in patients with recurrent or metastatic cervical cancer: post hoc analyses from the open-label, randomized, phase 3 ENGOT-cx12/GOG-3057/innovaTV 301 trial.

Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

Published: May 19, 2026

Antibody-drug conjugates in gynaecological cancers: opportunities and challenges.

Antibody-drug conjugates in gynaecological cancers: opportunities and challenges.

Journal: Nature reviews. Clinical oncology

Published: May 18, 2026

Tissue Factor-High Ovarian Clear Cell Carcinoma Shows Immune-Cold Features and Preclinical Activity of Tisotumab Vedotin.

Tissue Factor-High Ovarian Clear Cell Carcinoma Shows Immune-Cold Features and Preclinical Activity of Tisotumab Vedotin.

Journal: Cancer science

Published: March 31, 2026

Antibody-drug conjugates in selected solid tumours: a position statement update based on findings from the third workshop held by the ETOP IBCSG Partners Foundation.

Antibody-drug conjugates in selected solid tumours: a position statement update based on findings from the third workshop held by the ETOP IBCSG Partners Foundation.

Journal: ESMO open

Published: March 10, 2026

Development, Validation, and Application of an LC-MS/MS Method for Pharmacokinetic Studies for the Datopotamab Deruxtecan-Dlnk Quantification in Rat Plasma.

Development, Validation, and Application of an LC-MS/MS Method for Pharmacokinetic Studies for the Datopotamab Deruxtecan-Dlnk Quantification in Rat Plasma.

Journal: Biomedical chromatography : BMC

Published: March 04, 2026

Molecular Profiling of Tisotumab Vedotin-Treated Patients Identifies Immune Pathways Associated With Clinical Activity.

Molecular Profiling of Tisotumab Vedotin-Treated Patients Identifies Immune Pathways Associated With Clinical Activity.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: February 25, 2026

Are patient factors associated with real-world antibody-drug conjugate outcomes in gynecologic cancers?

Are patient factors associated with real-world antibody-drug conjugate outcomes in gynecologic cancers?

Journal: Gynecologic oncology

Published: February 23, 2026

Showing 1-12 of 122

Last Updated: 09/26/2026